Aquestive Therapeutics (AQST) Enterprise Value (2017 - 2026)

Aquestive Therapeutics' Enterprise Value history runs 10 years deep, the most recent figure standing at -$110.7 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 61.29% year-over-year to -$110.7 million in Q1 2026; TTM through Mar 2026 was -$110.7 million, a 61.29% decrease from a year earlier, with the FY2025 full-year figure at -$121.2 million, down 69.36% from the prior year.
• Enterprise Value improved to -$110.7 million in Q1 2026 per AQST's latest filing, from -$121.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$14.7 million in Q1 2022 and bottomed at -$129.1 million in Q3 2025.
• The 5-year median for Enterprise Value is -$60.5 million (2025), against an average of -$58.9 million.
• Across the five-year window, Enterprise Value soared 48.31% in 2022 and sank 300.56% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$27.3 million in 2022, then increased by 12.47% to -$23.9 million in 2023, then sank by 199.71% to -$71.5 million in 2024, then tumbled by 69.36% to -$121.2 million in 2025, then gained by 8.61% to -$110.7 million in 2026.
• Per Business Quant, the three latest AQST Enterprise Value figures stand at -$110.7 million (Q1 2026), -$121.2 million (Q4 2025), and -$129.1 million (Q3 2025).